Continuous vs Cyclic HRT: Which One Is Right for You?
Continuous vs cyclic HRT is really a question of timing. Continuous combined HRT supplies estrogen and a progestogen throughout the cycle — every day for pills, or on a steady patch schedule — and aims for no monthly bleed. Cyclic HRT (also called cyclical or sequential) supplies estrogen throughout and adds the progestogen for part of each month, which usually brings a planned bleed. Cyclic is common while you still have periods; continuous is common once you're past menopause.
That's the short answer. But here's what the leaflet probably didn't tell you: the two schedules don't just change your bleeding — they nudge your breast and womb cancer risks in different directions, and "safer" is not as simple as it sounds. We put the real numbers below so you can see for yourself.
Usually fits you if…
Continuous combined HRT
It's been 12+ months since your last period, you have a uterus and need womb-lining protection, and you'd rather skip a monthly bleed.
Usually fits you if…
Cyclic (sequential) HRT
You still get periods — even irregular ones — or your last natural period was recent, and a scheduled monthly bleed is fine with you.
Don't pick a schedule from this page alone if:
You're unsure of your uterus status, your bleeding is heavy or unexplained, you've had endometrial ablation or complex uterine surgery, you still need contraception, or your health history needs an individual review. Those belong with a clinician first.
At a glance
| Continuous combined HRT | Cyclic / sequential HRT | |
|---|---|---|
| How you take it | Estrogen and progestogen throughout the cycle | Estrogen throughout; progestogen for part of each month |
| Planned bleeding | Aims for no monthly bleed | A withdrawal bleed is usually expected |
| Usually for | After menopause (12+ months, no period) | Still having periods, or stopped recently |
| Main tradeoff | Everyday progestogen; early spotting possible | A monthly bleed; weaker long-term womb protection over years |
| Is it birth control? | No | No |
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated.
We'll be straight with you: we can't tell you which schedule is right for you, and any page that claims it can is guessing. What we can do is hand you the same facts a good clinician would walk you through — the differences, the bleeding, the real risk numbers, and the exact questions to ask — so you walk into your appointment already halfway to a decision.
What's the difference between continuous and cyclic HRT?
Both are forms of combined HRT — estrogen plus a progestogen. The only structural difference is when the progestogen is taken. Continuous combined HRT gives both hormones throughout the cycle. Cyclic (sequential) HRT gives estrogen throughout and adds the progestogen for part of each month, usually followed by a bleed.
A quick definition first, because the words get thrown around. Progestogen is the umbrella term for progesterone (the hormone your body makes) and progestins (lab-made versions). Its job in HRT is to protect the lining of your womb. We'll use "progestogen" from here.
Why does that lining need protecting? Because estrogen on its own makes the womb lining thicken, and over time that overgrowth — called endometrial hyperplasia — can raise the risk of womb cancer. Adding a progestogen keeps the lining in check. That's why a progestogen is added whenever systemic estrogen is used by someone who still has a womb.
"Combined" doesn't always mean "continuous"
- Combined HRT = estrogen plus a progestogen (in one product or two).
- Continuous combined HRT = both hormones, throughout the cycle.
- Sequential (cyclic) HRT = estrogen throughout, progestogen for part of the month.
So "combined" tells you what's in it. "Continuous" or "cyclic" tells you how it's timed.
Cyclic, cyclical, sequential — same idea
If you've seen all three words and wondered if they're different treatments: they're not. Cyclic, cyclical, and sequential all describe the same approach — progestogen for part of the cycle, then a bleed. With sequential regimens, the progestogen is usually taken about 12 to 14 days a month when it's micronized progesterone; some products using synthetic progestins use around 10 days. The day-count varies; the concept is the same.
What this page does not cover
We're talking about systemic combined HRT — the kind that travels through your whole body and is used mainly for moderate-to-severe hot flashes and night sweats. Many women also notice better sleep and mood, though those aren't the formal approved uses.
Low-dose vaginal estrogen — creams, tablets or inserts, and the Estring ring — is a separate question with a different risk profile, and the continuous-versus-cyclic decision generally doesn't apply to it the same way. One catch worth knowing: not every ring is "local." The Femring ring delivers systemic estrogen and is approved for hot flashes, so it's not in the same low-dose category as Estring. If vaginal estrogen is what you're weighing, see our vaginal estrogen guide.
Who is each schedule usually for?
The first two decision gates are whether you have a uterus and how long it's been since your last period. Cyclic HRT is the common starting point while periods are still happening or stopped recently. Continuous combined HRT is commonly discussed once menopause is established (usually 12+ months period-free). Age, premature ovarian insufficiency, contraception needs, bleeding, and prior surgery can all change the answer.
If you still have periods
When your ovaries are still active — even sputtering on and off in perimenopause — your own hormones are still rising and falling. A no-bleed continuous regimen laid on top of that tends to cause messy, hard-to-read spotting. So cyclic HRT, which works with a monthly rhythm and gives a planned bleed, is usually the smoother fit.
If it's been at least a year since your last natural period
Once you've gone a full 12 months with no period, you're considered postmenopausal, and continuous combined HRT is commonly discussed. The payoff for many women is no monthly bleed over time, plus the schedule with the strongest long-term womb protection. Bleeding generally becomes less frequent the longer you're on it — though the share of women who become completely bleed-free varies a lot by product, dose, and route.
Why uterus status comes first
Most systemic estrogen regimens for someone with a uterus need a progestogen plan to protect the lining. There's one notable US exception: Duavee (conjugated estrogens paired with bazedoxifene) is FDA-approved for eligible postmenopausal women with a uterus, and it uses bazedoxifene — an estrogen agonist/antagonist, not a progestogen — for that protection. It sits outside this continuous-versus-cyclic comparison. And if you've had your uterus removed (hysterectomy), the picture changes again — estrogen-only HRT is usually the option your clinician will discuss.
The situations that don't fit the simple two-column answer
Real life is messier than a chart. Talk to a clinician — not a website — if any of these apply:
- •A subtotal (partial) hysterectomy, because some womb-lining tissue may remain
- •A total hysterectomy with endometriosis or another condition that may change the usual estrogen-only approach
- •A history of endometrial ablation — combined HRT is generally still used afterward, because some lining can remain
- •Premature ovarian insufficiency (POI) — menopause before 40, where younger women can sometimes use continuous regimens earlier
- •An uncertain last natural period
- •You still need contraception
- •Any unexplained bleeding
Find your fit in about 90 seconds
You understand the categories now — but "where do I land?" depends on details a general page can't see. The HRT Index's quiz asks a few private questions about your symptoms, stage, uterus status, and preferences, then shows your best-fit online care route, why it fits, and two strong backups — with FDA-approved and compounded options clearly labeled. No email, and your answers never leave the page.
Find My HRT Path →Will continuous HRT stop my periods — and will cyclic HRT make me bleed?
Cyclic HRT is designed to give a withdrawal bleed after the progestogen days — and that bleed is not proof you ovulated. Continuous combined HRT aims for no bleeding over time, but light, irregular spotting in the early months is common while your body adjusts. The line that matters: bleeding that's heavy or prolonged, or that shows up after a settled bleed-free stretch, should be checked.
A withdrawal bleed is not the same as a real period
On cyclic HRT, the bleed after the progestogen phase is a withdrawal bleed — it happens because the hormone level drops, not because your ovaries released an egg. It can look and feel like a period, but it's a response to the medicine.
"How do I even know when I've reached menopause on cyclic HRT?"
This is one of the most honest questions women ask, and there's no tidy home test for it. Because cyclic HRT gives a monthly bleed, it can mask the natural sign — your periods stopping — that you'd normally use to mark menopause. The takeaway: don't assume your monthly bleed proves your ovaries are still active, but don't assume they're not. That judgment belongs with your clinician.
Why spotting can happen after starting continuous HRT
When you first move to a no-bleed schedule, your womb lining needs time to settle into everyday progestogen. Light spotting or irregular bleeding in the early months is common and, on its own, usually not alarming. But "usually fine early on" is not the same as "ignore it forever."
Keep a simple bleeding diary
If you do bleed, a few notes make your appointment far more useful. Track:
- ✓The date
- ✓How heavy it is
- ✓How long it lasts
- ✓Where it falls relative to your progestogen days (if you're on cyclic)
- ✓Any missed or late doses
- ✓Any recent change in dose or product
- ✓The date of your last clearly natural period
When bleeding needs a clinician — not a forum
Please don't assume all bleeding is just "settling in." Get medical advice promptly for any of these (current UK British Menopause Society guidance):
- •Heavy or prolonged bleeding, at any time
- •New bleeding that starts more than 6 months after beginning HRT
- •New bleeding more than 3 months after a dose or product change
- •Bleeding that returns after a settled bleed-free stretch
Each of those warrants assessment. In the US, ACOG updated its guidance in April 2026 to recommend that most people evaluated for postmenopausal bleeding get both a transvaginal ultrasound and an endometrial tissue sample — because about 9 in 10 womb cancers show up as postmenopausal bleeding, and ultrasound alone can miss some.
Is continuous or cyclic HRT safer?
There's no honest one-word winner. Continuous combined HRT is linked to lower womb-cancer risk and gives stronger lining protection. For breast cancer, sequential (cyclic) HRT carries a slightly lower risk than continuous — but both are a little higher than taking no HRT. The right balance depends on your history, your dose, and how long you use it — not on a slogan.
Womb (endometrial) cancer: continuous comes out ahead
Because continuous combined HRT delivers progestogen throughout the cycle, it keeps the lining thin. Using NICE's UK figures for women aged 50 to 54 (measured over 5 years): about 4 in 1,000 who never take HRT develop womb cancer, versus about 1 in 1,000 on continuous combined HRT (3 fewer) and about 8 in 1,000 on sequential HRT (4 more). So continuous combined is associated with lower womb-cancer risk than no HRT, while sequential HRT may slightly increase it — more so with longer use, fewer progestogen days per cycle, or a higher estrogen dose. (For comparison, estrogen alone in someone with a uterus runs about 11 in 1,000 — which is exactly why a progestogen is added.)
Breast cancer: cyclic is slightly lower — and the time window matters
Here's the trade in the other direction, and a number a lot of pages get wrong. NICE's breast-cancer figures are measured over 20 years (ages 50 to 69), not over a 5-year window:
| Scenario | Cases per 1,000 women (20 yrs) | Extra cases vs no HRT |
|---|---|---|
| No HRT | ~59 in 1,000 | baseline |
| 5 years combined HRT from age 50 | ~79 in 1,000 | +20 more |
| 10 years combined HRT from age 50 | ~92 in 1,000 | +33 more |
Source: NICE NG23 discussion aid (UK). Figures measured over 20 years, ages 50–69. NICE separately states that sequential combined HRT carries a lower breast-cancer risk than continuous combined HRT, though both are higher than no HRT. The risk falls again after you stop.
Here's the part most pages skip
Neither schedule is "safer" across the board, and neither is free of downsides. Continuous combined HRT carries a slightly higher breast-cancer signal — but stronger womb protection. Cyclic carries a slightly lower breast signal — but weaker womb protection over many years, plus a monthly bleed you have to live with.
If breast-cancer risk is what weighs on you most, that's a real reason to ask your clinician about a sequential regimen — and if you've had a hysterectomy, to ask whether estrogen-only is right for you (our HRT benefits and risks page covers the broader risk picture). For most postmenopausal women with a uterus, the everyday-progestogen approach is the common choice precisely because it protects the lining best, and the breast difference is small in absolute terms.
A current note on labeling (February 2026)
On February 12, 2026, the FDA approved labeling changes to the first six menopausal hormone therapy products, removing the cardiovascular-disease, breast-cancer, and probable-dementia statements from those products' boxed warning. Detailed benefit and risk information stays in the product labeling. This doesn't change the schedule tradeoffs above — but check your own product's current label.
How does the progestogen change in continuous vs cyclic HRT?
The timing of the progestogen changes. Cyclic regimens use it for part of each month; continuous regimens use it throughout. The exact dose depends on the product, your estrogen dose, the route, and your history — so treat the examples below as illustrations of the schedule, never as a dose to copy.
Current US prescribing-label examples (checked June 2026)
Confirm any product's current label with your pharmacist or clinician — labels and supply change.
| Product | Hormones | Schedule it shows |
|---|---|---|
| Prempro | Conjugated estrogens + medroxyprogesterone | Continuous combined (once daily) |
| Bijuva | Estradiol + progesterone | Continuous combined (FDA-approved estradiol/progesterone combination) |
| Activella · Angeliq | Estradiol + norethindrone · estradiol + drospirenone | Continuous combined |
| CombiPatch | Estradiol + norethindrone (patch) | Continuous combined OR continuous sequential, depending on the labeled regimen |
| Climara Pro | Estradiol + levonorgestrel (patch) | Continuous combined |
| Premphase | Conjugated estrogens + medroxyprogesterone | Cyclic — estrogen alone on days 1–14, estrogen + progestogen on days 15–28 (withdrawal bleed) |
| Estradiol + Prometrium (separate) | Estradiol (patch/gel/pill) + oral micronized progesterone | Cyclic. Prometrium's FDA-labeled regimen is 200 mg at bedtime for 12 days of a 28-day cycle alongside daily conjugated-estrogen tablets |
About that last row: those are separately FDA-approved components. Whether your exact estrogen–progesterone pairing, route, and schedule is FDA-labeled depends on the specific products — some clinician-prescribed combinations are off-label. In US practice, a cyclic plan is often built from separate components like these rather than from a single cyclic box. For more on micronized progesterone doses, see our dedicated guide.
Schedule is not the same as route
A skin patch can be part of either a continuous or a cyclic plan. The route (patch, pill, gel) is a separate decision from the schedule. Don't let "patch" or "pill" make you assume one schedule.
Schedule is NOT the same as FDA-approval status
- • An FDA-approved product can be prescribed on a continuous or a cyclic schedule.
- • A compounded product can also be prescribed on either schedule.
- • The words continuous, cyclic, bioidentical, or micronized do not, by themselves, tell you whether something is FDA-approved.
On compounded hormones
Compounded drugs are not FDA-approved. The FDA doesn't review them for safety, effectiveness, or quality before they're sold, and poor compounding can mean contamination or too much or too little active ingredient. The FDA has said it has no evidence that compounded "bioidentical" hormones are safer or more effective than FDA-approved therapy. Bijuva is an FDA-approved combination containing estradiol and progesterone — that is not the same as a custom-compounded "bioidentical" prescription. Keep those two ideas separate.
Can I use continuous HRT during perimenopause?
Sometimes, in selected cases — but with caveats. While your ovaries are still active, bleeding tends to be unpredictable on a no-bleed schedule, which is why cyclic HRT is the common perimenopausal choice. And one rule holds either way: menopausal HRT is not contraception.
Why cyclic is the usual perimenopause pick
It comes back to your own hormones still firing. A schedule built around a monthly rhythm copes with that better than a daily no-bleed schedule, which often just produces erratic spotting in perimenopause.
Why continuous might still come up
We won't tell you it's forbidden — that's not true. Whether a continuous approach makes sense in perimenopause depends on your age, how your cycles are behaving, your goals, and any other medications. It's a real conversation, not a closed door.
HRT is not birth control — read this twice
Neither continuous nor cyclic menopausal HRT should be relied on for contraception. If pregnancy is still possible for you, that's a separate discussion from your HRT. And it cuts both ways: hormonal contraception can also hide the signs you'd use to tell whether you've reached menopause. So if you still need pregnancy prevention, raise it directly — don't assume your HRT covers it.
When a hormonal IUD changes the conversation
A 52-mg levonorgestrel IUD (such as Mirena) is sometimes used off-label in the US to deliver the progestogen for womb-lining protection during HRT. Its FDA-approved US uses are contraception and treating heavy periods; the HRT use is off-label here, though it's an established option in the UK. This is a clinician decision, not a DIY plan.
When should I switch from cyclic to continuous HRT?
A switch is usually discussed once menopause is established — often around 12 months period-free, or after a stretch on sequential HRT — especially when the monthly bleed becomes a burden. Long-term sequential use is itself a reason to review. The timing is individual, and you shouldn't stop or rearrange your progestogen on your own.
Common reasons it comes up
- ✓Menopause now looks established
- ✓The monthly bleed has become a burden
- ✓The current routine is hard to stick to
- ✓You're changing product or route anyway
- ✓Progestogen-linked symptoms need a rethink
What current UK guidance says
The British Menopause Society suggests that women over 45 on sequential HRT be offered a switch to continuous combined after about five years of sequential use, or by age 54, whichever comes first — partly because long-term sequential use carries that small extra womb-cancer signal. It also says an earlier trial of continuous combined can be considered after about 12–18 months. This is UK guidance, not a US rule, but it's a useful benchmark to raise with your clinician.
What to expect after switching
Moving to a no-bleed schedule can bring some spotting while your lining adjusts — same as starting continuous from scratch. Early spotting is common. But it shouldn't get unlimited benefit of the doubt: persistent or new-after-bleed-free bleeding still needs review.
What you should not change on your own
- •Don't skip required progestogen — your womb protection depends on it
- •Don't copy a dose from a label example
- •Don't read "no bleeding" as proof the schedule suits you
- •Don't read "a monthly bleed" as proof you're fertile
Think you might be ready to switch?
Find My HRT Path shows which online providers serve your state and could manage that change — your best-fit route, why it fits, and two backups, in about 90 seconds, with no email and nothing stored. A licensed clinician still makes the final call.
Find My HRT Path →What if I feel worse during the progestogen phase?
If symptoms reliably cluster during your progestogen days, that pattern is worth writing down and raising — not ignoring, and not treating as proof that all progesterone is wrong for you. A clinician can review the timing, product, route, and estrogen dose while keeping any womb protection you medically need.
Some women feel low mood, bloating, breast tenderness, or irritability that seems to line up with the part-month progestogen. Here's how to handle it well.
Track the timing before you conclude anything
Use a quick symptom-and-dose log for a month or two, noting when symptoms hit and where they fall relative to your progestogen days (our symptoms checklist is a good starting point). Patterns beat impressions.
Questions your clinician may work through
- →Do the symptoms truly line up with the progestogen days?
- →Has the estrogen dose or route changed recently?
- →Are doses being missed or taken late?
- →Could another medical or medication factor explain it?
- →Is a different, clinically appropriate progestogen strategy available?
Why stopping progestogen on your own can be unsafe
If you have a uterus and need lining protection, dropping or skipping the progestogen to dodge side effects leaves your lining exposed to estrogen — the exact risk the progestogen is there to prevent. There are often safer ways to adjust (a different progestogen, a different schedule, a route change) that keep the protection while easing the symptom. That's a conversation, not a solo experiment.
How do continuous and cyclic HRT compare, side by side?
The useful question isn't only "which is better?" — it's "which schedule fits my uterus status, menopause stage, bleeding goal, risk history, and contraception need?" The matrix below separates those, with the source and check date for every material point.
This matrix compares scheduling patterns. It does not select or dose treatment for any individual. "Continuous" and "cyclic" describe when hormones are used — not whether a product is FDA-approved.
| Decision factor | Continuous combined HRT | Cyclic / sequential HRT | Conditions & source |
|---|---|---|---|
| Core schedule | Estrogen + progestogen throughout the cycle | Estrogen throughout; progestogen part of the month | Standard schedule descriptions (NHS, UK) |
| Common starting context | After menopause is established | While periods continue or stopped recently | A usual pattern, not a personal rule (UK guidance) |
| Planned bleeding | Aims for no bleed; early spotting can occur | Withdrawal bleed usually expected | A withdrawal bleed ≠ ovulation |
| Bleed-free over time | Becomes more likely with time; rate varies by product, dose, route | Monthly bleed by design | No single cross-product percentage |
| Uterus gate | Systemic estrogen + a uterus = progestogen plan (Duavee is a non-progestogen exception) | Same protection principle | Hysterectomy/ablation/endometriosis change the question (US: Duavee label) |
| Womb (endometrial) cancer | ~1 in 1,000 vs ~4 with no HRT — lower | ~8 in 1,000 — slightly higher, more so with longer use | Ages 50–54, 5-yr window (NICE, UK) |
| Breast cancer | Slightly higher than sequential | Lower than continuous; both higher than no HRT | Combined: +20/1,000 at 5 yrs, +33 at 10 yrs over a 20-yr window (NICE, UK) |
| Overall 'safer' verdict | No universal winner | No universal winner | Womb and breast risks move in opposite directions |
| Contraception | Not contraception | Not contraception | A separate discussion if pregnancy is possible |
| US label examples | Prempro, Bijuva, Activella, Angeliq, Climara Pro; CombiPatch (both regimens) | Premphase; or estradiol + cyclic Prometrium (separate components) | Examples of label patterns only; some combinations are off-label (US, checked Jun 2026) |
| FDA-approved vs compounded | Either an approved or compounded product can be used | Same | Schedule never proves approval status; compounded is not FDA-approved (FDA) |
| Switching | Usually the destination, once menopause is established | May stay appropriate while timing is uncertain | UK: offer switch after ~5 yrs sequential or by age 54 |
| Bleeding that changes the plan | Persistent, heavy, or new-after-bleed-free → review | Bleeding outside the expected pattern → review | UK BMS thresholds; US ACOG evaluation |
| Important exceptions | May not resolve the plan after hysterectomy/ablation, in POI, with endometriosis, or with complex bleeding | Same exceptions | Route to individualized or in-person care |
How to read this matrix
- Verified fact = traceable to a source in the list below.
- Editorial interpretation = our plain-language read of those facts.
- Individual variable = depends on you; a clinician decides.
It can't assess your medical history, find the cause of a specific bleed, set a dose, or confirm what you're eligible for. It narrows the question and tells you what to ask. The decision still happens with a clinician.
What should I ask before changing my HRT schedule?
Before changing anything, get clear on five things: whether you need womb protection, whether your bleeding is expected, exactly what you're taking (and its approval status), whether you still need contraception, and what follow-up looks like. Leave the appointment knowing what to do after a missed dose and which bleeding patterns mean "call the office."
Your consult checklist — screenshot or print this
- 1Do I have an intact uterus or any remaining womb tissue?
- 2Is this bleeding expected for my current schedule?
- 3Could I still be ovulating, or do I need contraception separately?
- 4What exact estrogen and progestogen products am I using?
- 5Is each one FDA-approved or compounded?
- 6Does my progestogen plan fully protect my womb lining?
- 7Why are we considering a switch now?
- 8What should I expect in the first few months after switching?
- 9What do I do if I miss a progestogen dose?
- 10Which bleeding patterns need an exam, a scan, or a biopsy?
- 11When is my follow-up?
- 12What would make us reconsider the schedule later?
Bring the names, not just "my HRT"
Walk in with your actual medication list (photos of the boxes work great), your bleeding dates, and any relevant surgery details. "I'm on some HRT" slows the visit down. Specifics speed it up.
When is online menopause care not the right starting point?
Online care can be a great way to start treatment discussions — but it can't replace an in-person exam when one is needed. Skip straight to in-person care if bleeding needs a physical exam, scan, or tissue sample; if your history is unusually complex; or if symptoms are urgent.
Bleeding that needs an exam or testing
Persistent, heavy, prolonged, or unexplained bleeding — and especially new bleeding after a settled bleed-free stretch — generally needs an in-person assessment, not a video visit alone. In the US, ACOG's April 2026 guidance points most of these evaluations toward both ultrasound and a tissue sample. A questionnaire can't feel a pelvis or run a scan.
A complex uterine or cancer history
If your history is complicated, you deserve more than automated routing off a few questions. That's a person-to-person evaluation.
Pregnancy uncertainty or unresolved contraception
If pregnancy is still possible, sort that out directly and separately from your HRT. It changes the picture.
Symptoms that need urgent care
Call emergency services for chest pain or pressure, trouble breathing, weakness or numbness on one side, sudden severe headache, trouble speaking, or pain and swelling in one leg — these can be signs of a heart, stroke, or blood-clot emergency. That's an emergency-care question, not an online one.
How did The HRT Index verify this comparison?
This page is editorial research produced under The HRT Index Verification Standard — our documented process for evaluating online HRT providers. For this article, we checked the schedules and the womb-protection principle against menopause-society and national guidance, the risk numbers against NICE, the US product examples against FDA prescribing information, the FDA-approved-versus-compounded line against FDA material, and the bleeding guidance against current British Menopause Society and ACOG resources.
Who made this
Written by The HRT Index Editorial Team. We use a real, accountable byline. This version was not reviewed by a clinician, and we say so plainly rather than attach a name or credential we didn't earn — see our medical review policy.
How we worked:
- •Sources were ranked by authority and relevance.
- •Every medical and regulatory conclusion came from a primary or authoritative source.
- •Provider marketing was not used to judge clinical suitability.
- •Reader discussions were used only to understand real-world wording and worries — never as medical evidence.
What we actually verified for this page
- ✓The defining hormone schedules, against national and society guidance
- ✓Typical menopause-stage use, against that guidance
- ✓Breast and womb cancer numbers, against NICE's discussion aid
- ✓US product examples, against FDA prescribing information
- ✓FDA-approved vs compounded status, against FDA material
- ✓Bleeding-evaluation guidance, against current BMS (UK) and ACOG (US) resources
We did not decide which regimen is right for any individual, verify every possible product combination, or set one universal date for switching schedules.
Spot something off? Tell us. Every correction is logged at our corrections page with the date and a visible "Updated" stamp on the affected page. Read about our full evaluation methodology.
Continuous vs cyclic HRT: FAQ
Is cyclic HRT the same as sequential HRT?+
Is combined HRT always continuous?+
Do you still get a period on cyclic HRT?+
Can continuous HRT stop periods?+
How long can spotting last after starting continuous HRT?+
What if I don't have a withdrawal bleed on cyclic HRT?+
Can I use continuous HRT while I'm still having periods?+
Can I stay on cyclic HRT after menopause?+
Which schedule protects the womb lining better?+
Which schedule has lower breast-cancer risk?+
Is continuous HRT safer overall?+
Is menopausal HRT birth control?+
Do I need progesterone after a hysterectomy?+
Is there a systemic-estrogen option for a woman with a uterus that doesn't use a progestogen?+
Does a hormonal IUD change the schedule?+
Can progesterone cream or gel protect the womb lining?+
What should I do if I miss a progesterone dose?+
Can I switch schedules without talking to my clinician?+
Does "continuous" mean FDA-approved?+
Are separately FDA-approved estrogen and progesterone products automatically an FDA-approved combination?+
Is every vaginal estrogen ring "local"?+
Is vaginal estrogen part of this comparison?+
Does bleeding mean my HRT isn't working?+
Still not sure which HRT path is right for you?
Take our free 60-second matching quiz and get your best-fit online care route — with FDA-approved and compounded options clearly labeled, two backups, and no email required. Your answers never leave the page.
Take the free HRT quiz →How we handle health data. A licensed clinician always makes the final treatment decision.
Sources
- 1.NHS — Types of hormone replacement therapy (HRT). United Kingdom. Schedule definitions, who each fits, expected bleeding. Accessed June 2026.
- 2.NICE — HRT and the likelihood of some medical conditions: a discussion aid (NICE Guideline NG23). United Kingdom, 2024. Absolute breast and womb cancer numbers. Accessed June 2026.
- 3.NICE NG23 — Table 1: Combined HRT versus no HRT: effect on specific health outcomes. United Kingdom, 2024. Breast and womb cancer risk direction. Accessed June 2026.
- 4.British Menopause Society — Management of unscheduled bleeding on HRT. United Kingdom. Bleeding-evaluation thresholds. Accessed June 2026.
- 5.British Menopause Society — HRT and breast cancer risk (Tools for Clinicians, 2025) and progestogens/endometrial-protection guidance. United Kingdom. Continuous-vs-sequential breast comparison; switching guidance. Accessed June 2026.
- 6.U.S. Food & Drug Administration — Menopause (women's health topics) and Compounding and the FDA: Questions and Answers. United States. FDA-approved vs compounded status. Accessed June 2026.
- 7.U.S. Food & Drug Administration — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (news release, February 12, 2026). United States. Boxed-warning labeling change. Accessed June 2026.
- 8.FDA prescribing information (DailyMed / Drugs@FDA) — Prempro, Premphase, Bijuva, Activella, Angeliq, CombiPatch, Climara Pro, Prometrium, Duavee, Estring, Femring. United States. Product schedules and labeled regimens. Accessed June 2026.
- 9.American College of Obstetricians and Gynecologists — Updated Guidance on Evaluation of Postmenopausal Bleeding (April 16, 2026). United States. Initial evaluation with transvaginal ultrasound plus endometrial sampling. Accessed June 2026.
Last verified: June 2026. This page is editorial research and is not medical advice. FDA-approved and compounded options are labeled distinctly throughout; compounded medication is never implied to be equivalent to, safer than, or more natural than FDA-approved medication. Risk figures from NICE and the British Menopause Society are UK estimates; product and regulatory facts are from the US FDA and ACOG. Always discuss your treatment with a qualified clinician.